<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KETEK - telithromycin tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>KETEK<span class="Sup">®</span><br>(telithromycin) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Ketek is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</span> There have been reports of fatal and life-threatening <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> associated with the use of Ketek. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">KETEK<span class="Sup">®</span> tablets contain telithromycin, a semisynthetic antibacterial in the ketolide class for oral administration. Chemically, telithromycin is designated as Erythromycin,  3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-.</p>
<p>Telithromycin, a ketolide, differs chemically from the macrolide group of antibacterials by the lack of α-L-cladinose at position 3 of the erythronolide A ring, resulting in a 3-keto function. It is further characterized by a C11-12 carbamate substituted by an imidazolyl and pyridyl ring through a butyl chain. Its empirical formula is C<span class="Sub">43</span>H<span class="Sub">65</span>N<span class="Sub">5</span>O<span class="Sub">10 </span>and its molecular weight is 812.03. Telithromycin is a white to off-white crystalline powder. The following represents the chemical structure of telithromycin. </p>
<p><br><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ba1cca98-f350-4655-88e3-6ef990779fb9&amp;name=ketek-01.jpg"><br> 	</p>
<p>KETEK tablets are available as light-orange, oval, film-coated tablets, each containing 400 mg or 300 mg of telithromycin, and the following inactive ingredients:  croscarmellose sodium, hypromellose,  magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, red ferric oxide, talc, titanium dioxide, and yellow ferric oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First"> Following oral administration, telithromycin reached maximal concentration at about 1 hour (0.5 – 4 hours). </p>
<p>It has an absolute bioavailability of 57% in both young and elderly subjects.</p>
<p>The rate and extent of absorption are unaffected by food intake, thus KETEK tablets can be given without regard to food.</p>
<p>In healthy adult subjects, peak plasma telithromycin concentrations of approximately 2 µg/mL are attained at a median of 1 hour after an 800-mg oral dose. </p>
<p>Steady-state plasma concentrations are reached within 2 to 3 days of once daily dosing with telithromycin 800 mg.</p>
<p>Following oral dosing, the mean terminal elimination half-life of telithromycin is 10 hours.</p>
<p>The pharmacokinetics of telithromycin after administration of single and multiple (7 days) once daily 800-mg doses to healthy adult subjects are shown in Table 1.</p>
<a name="ie7f45f53-7fc4-48af-8499-0f05c7149442"></a><table width="60%">
<caption><span>Table 1</span></caption>
<col align="left" valign="middle" width="34%">
<col align="left" valign="middle" width="33%">
<col align="left" valign="middle" width="33%">
<thead>
<tr class="Botrule First">
<th align="left"></th>
<th align="center" colspan="2">Mean (SD)</th>
</tr>
<tr class="Last">
<th align="left">Parameter</th>
<th align="left">Single dose (n=18)</th>
<th align="left">Multiple dose (n=18)</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">SD=Standard deviation</td></tr>
<tr><td align="left" colspan="3">C<span class="Sub">max</span>=Maximum plasma concentration</td></tr>
<tr><td align="left" colspan="3">T<span class="Sub">max</span>=Time to C<span class="Sub">max</span>
</td></tr>
<tr><td align="left" colspan="3">AUC=Area under concentration vs. time curve</td></tr>
<tr><td align="left" colspan="3">t<span class="Sub">1/2</span>=Terminal plasma half-life </td></tr>
<tr class="Last"><td align="left" colspan="3">C<span class="Sub">24h</span>=Plasma concentration at 24 hours post-dose</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Median (min–max) values</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="left">     1.9 (0.80)</td>
<td align="left">     2.27 (0.71)</td>
</tr>
<tr>
<td align="left">T<span class="Sub">max</span> (h)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="left">     1.0 (0.5–4.0)</td>
<td align="left">     1.0 (0.5–3.0)</td>
</tr>
<tr>
<td align="left">AUC<span class="Sub">(0–24)</span> (µg∙h/mL)</td>
<td align="left">     8.25 (2.6)</td>
<td align="left">     12.5 (5.4)</td>
</tr>
<tr>
<td align="left">Terminal t<span class="Sub">1/2 </span>(h)</td>
<td align="left">     7.16 (1.3)</td>
<td align="left">     9.81 (1.9)</td>
</tr>
<tr class="Last">
<td align="left">C<span class="Sub">24h</span> (µg/mL)</td>
<td align="left">     0.03 (0.013)</td>
<td align="left">     0.07 (0.051)</td>
</tr>
</tbody>
</table>
<p>In a patient population, mean peak and trough plasma concentrations were 2.9 µg/mL (±1.55), (n=219) and 0.2 µg/mL (±0.22), (n=204), respectively, after 3 to 5 days of KETEK 800 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Total <span class="Italics">in vitro</span> protein binding is approximately 60% to 70% and is primarily due to human serum albumin.</p>
<p>Protein binding is not modified in elderly subjects and in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>The volume of distribution of telithromycin after intravenous infusion is 2.9 L/kg.</p>
<p>Telithromycin concentrations in bronchial mucosa, epithelial lining fluid, and alveolar macrophages after 800 mg once daily dosing for 5 days in patients are displayed in Table 2.</p>
<a name="i35995767-fdae-4ea0-81fc-6e844039acbc"></a><table width="75%">
<caption><span>Table 2</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th align="left" rowspan="2"></th>
<th align="center" rowspan="2" valign="bottom"> Hours<br>post-dose</th>
<th align="center" colspan="2">Mean concentration (µg/mL)</th>
<th align="center" rowspan="2" valign="bottom">Tissue/Plasma Ratio</th>
</tr>
<tr class="Last">
<th align="center">Tissue or<br>fluid</th>
<th align="center" valign="bottom">Plasma</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Units in mg/kg</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Bronchial mucosa</td>
<td align="center">2</td>
<td align="center">3.88<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">1.86</td>
<td align="center">2.11</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">12</td>
<td align="center">1.41<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">0.23</td>
<td align="center">6.33</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center">24</td>
<td align="center">0.78<a href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">0.08</td>
<td align="center">12.11</td>
</tr>
<tr>
<td align="left">Epithelial lining fluid</td>
<td align="center">2</td>
<td align="center">14.89</td>
<td align="center">1.86</td>
<td align="center">8.57</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">12</td>
<td align="center">3.27</td>
<td align="center">0.23</td>
<td align="center">13.8</td>
</tr>
<tr class="Botrule">
<td align="left"></td>
<td align="center">24</td>
<td align="center">0.84</td>
<td align="center">0.08</td>
<td align="center">14.41</td>
</tr>
<tr>
<td align="left">Alveolar macrophages</td>
<td align="center">2</td>
<td align="center">65</td>
<td align="center">1.07</td>
<td align="center">55</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">8</td>
<td align="center">100</td>
<td align="center">0.605</td>
<td align="center">180</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="center">24</td>
<td align="center">41</td>
<td align="center">0.073</td>
<td align="center">540</td>
</tr>
</tbody>
</table>
<p>Telithromycin concentration in white blood cells exceeds the concentration in plasma and is eliminated more slowly from white blood cells than from plasma. Mean white blood cell concentrations of telithromycin peaked at 72.1 µg/mL at 6 hours, and remained at 14.1 µg/mL 24 hours after 5 days of repeated dosing of 600 mg once daily. After 10 days, repeated dosing of 600 mg once daily, white blood cell concentrations remained at 8.9 µg/mL 48 hours after the last dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">In total, metabolism accounts for approximately 70% of the dose. In plasma, the main circulating compound after administration of an 800-mg radio-labeled dose was parent compound, representing 56.7% of the total radioactivity. The main metabolite represented 12.6% of the AUC of telithromycin. Three other plasma metabolites were quantified, each representing 3% or less of the AUC of telithromycin. </p>
<p>It is estimated that approximately 50% of its metabolism is mediated by CYP 450 3A4 and the remaining 50% is CYP 450-independent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">The systemically available telithromycin is eliminated by multiple pathways as follows: 7% of the dose is excreted unchanged in feces by biliary and/or intestinal secretion; 13% of the dose is excreted unchanged in urine by renal excretion; and 37% of the dose is metabolized by the liver.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Special populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Gender</h3>
<p class="First">There was no significant difference between males and females in mean AUC, C<span class="Sub">max</span>, and elimination half-life in two studies; one in 18 healthy young volunteers (18 to 40 years of age) and the other in 14 healthy elderly volunteers (65 to 92 years of age), given single and multiple once daily doses of 800 mg of KETEK. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic insufficiency</span></h3>
<p class="First">In a single-dose study (800 mg) in 12 patients and a multiple-dose study (800 mg) in 13 patients with mild to severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (Child Pugh Class A, B and C), the C<span class="Sub">max</span>, AUC and t<span class="Sub">1/2</span> of telithromycin were similar to those obtained in age- and sex-matched healthy subjects. In both studies, an increase in renal elimination was observed in hepatically impaired patients indicating that this pathway may compensate for some of the decrease in metabolic clearance. No dosage adjustment is recommended due to <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>(See <span class="Bold"><a href="#General">PRECAUTIONS, General</a></span> and <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Renal_Insufficiency"></a><a name="section-3.2.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span></h3>
<p class="First">In a multiple-dose study, 36 subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> received 400 mg, 600 mg, or 800 mg KETEK once daily for 5 days. There was a 1.4-fold increase in C<span class="Sub">max,ss,</span> and a 1.9-fold increase in AUC (0–24)<span class="Sub">ss</span> at 800 mg multiple doses in the severely renally impaired group (CL<span class="Sub">CR</span> &lt; 30 mL/min) compared to healthy volunteers. Renal excretion may serve as a compensatory elimination pathway for telithromycin in situations where metabolic clearance is impaired. Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are prone to conditions that may impair their metabolic clearance. Therefore, in the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min), a reduced dosage of KETEK is recommended. (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>)</p>
<p>In a single-dose study in patients with end-stage <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> on hemodialysis (n=10), the mean C<span class="Sub">max</span> and AUC values were similar to normal healthy subjects when KETEK was administered 2 hours post-dialysis. However, the effect of dialysis on removing telithromycin from the body has not been studied. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Multiple_Insufficiency"></a><a name="section-3.2.4"></a><p></p>
<h3>Multiple insufficiency</h3>
<p class="First">The effects of co-administration of ketoconazole in 12 subjects (age ≥ 60 years), with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> were studied (CL<span class="Sub">CR</span>= 24 to 80 mL/min). In this study, when severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min, n=2) and concomitant impairment of CYP 3A4 metabolism pathway were present, telithromycin exposure (AUC (0–24)) was increased by approximately 4- to 5-fold compared with the exposure in healthy subjects with normal renal function receiving telithromycin alone. In the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min), with coexisting <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a reduced dosage of KETEK is recommended.  (See <span class="Bold"><a href="#General">PRECAUTIONS, General</a></span> and <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Geriatrics"></a><a name="section-3.2.5"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Pharmacokinetic data show that there is an increase of 1.4-fold in exposure (AUC) in 20 patients ≥ 65 years of age with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span> in a Phase III study, and a 2.0-fold increase in exposure (AUC) in 14 subjects ≥ 65 years of age as compared with subjects less than 65 years of age in a Phase I study.  No dosage adjustment is required based on age alone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Drug_Drug_Interaction"></a><a name="section-3.3"></a><p></p>
<h2>Drug-drug interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>In vitro interactions</h3>
<p class="First">In vitro studies using a model compound have shown that telithromycin may act as an inhibitor for the hepatic uptake transporters OATP1B1 and OATP1B3. Although the clinical relevance of this finding is unknown, it is possible that concomitant administration of telithromycin with drugs that are substrates of OATP family members could result in increased plasma concentrations of the co-administered drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>In vivo interactions</h3>
<p class="First">Studies were performed to evaluate the effect of CYP 3A4 inhibitors on telithromycin and the effect of telithromycin on drugs that are substrates of CYP 3A4 and CYP 2D6. In addition, drug interaction studies were conducted with several other concomitantly prescribed drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3"></a><p></p>
<h3>CYP 3A4 inhibitors</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3.1"></a><p></p>
<h4>Itraconazole</h4>
<p class="First">A multiple-dose interaction study with itraconazole showed that C<span class="Sub">max</span> of telithromycin was increased by 22% and AUC by 54%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3.2"></a><p></p>
<h4>Ketoconazole</h4>
<p class="First">A multiple-dose interaction study with ketoconazole showed that C<span class="Sub">max</span> of telithromycin was increased by 51% and AUC by 95%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3.3"></a><p></p>
<h4>Grapefruit juice</h4>
<p class="First">When telithromycin was given with 240 mL of grapefruit juice after an overnight fast to healthy subjects, the pharmacokinetics of telithromycin were not affected.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4"></a><p></p>
<h3>CYP 3A4 substrates</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4.1"></a><p></p>
<h4>Cisapride</h4>
<p class="First">Steady-state peak plasma concentrations of cisapride (an agent with the potential to increase QT interval) were increased by 95% when co-administered with repeated doses of telithromycin, resulting in significant increases in QTc. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4.2"></a><p></p>
<h4>Simvastatin</h4>
<p class="First">When simvastatin was co-administered with telithromycin, there was a 5.3-fold increase in simvastatin C<span class="Sub">max</span>, an 8.9-fold increase in simvastatin AUC, a 15-fold increase in the simvastatin active metabolite C<span class="Sub">max</span>, and a 12-fold increase in the simvastatin active metabolite AUC. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>)</p>
<p>In another study, when simvastatin and telithromycin were administered 12 hours apart, there was a 3.4-fold increase in simvastatin C<span class="Sub">max</span>, a 4.0-fold increase in simvastatin AUC, a 3.2-fold increase in the active metabolite C<span class="Sub">max</span>, and a 4.3-fold increase in the active metabolite AUC. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4.3"></a><p></p>
<h4>Midazolam</h4>
<p class="First">Concomitant administration of telithromycin with intravenous or oral midazolam resulted in 2- and 6-fold increases, respectively, in the AUC of midazolam due to inhibition of CYP 3A4-dependent metabolism of midazolam. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.5"></a><p></p>
<h3>CYP 2D6 substrates</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.5.1"></a><p></p>
<h4>Paroxetine</h4>
<p class="First">There was no pharmacokinetic effect on paroxetine when telithromycin was co-administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.5.2"></a><p></p>
<h4>Metoprolol</h4>
<p class="First">When metoprolol was co-administered with telithromycin, there was an increase of approximately 38% on the C<span class="Sub">max</span> and AUC of metoprolol, however, there was no effect on the elimination half-life of metoprolol. Telithromycin exposure is not modified with concomitant single-dose administration of metoprolol. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS, Drug interactions</a></span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Other_Drug_Interactions"></a><a name="section-3.3.6"></a><p></p>
<h3>Other drug interactions</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.1"></a><p></p>
<h4>Digoxin</h4>
<p class="First">The plasma peak and trough levels of digoxin were increased by 73% and 21%, respectively, in healthy volunteers when co-administered with telithromycin. However, trough plasma concentrations of digoxin (when equilibrium between plasma and tissue concentrations has been achieved) ranged from 0.74 to 2.17 ng/mL. There were no significant changes in ECG parameters and no signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. (See <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.2"></a><p></p>
<h4>Theophylline</h4>
<p class="First">When theophylline was co-administered with repeated doses of telithromycin, there was an increase of approximately 16% and 17% on the steady-state C<span class="Sub">max</span> and AUC of theophylline. Co-administration of theophylline may worsen gastrointestinal side effects such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, especially in female patients. It is recommended that telithromycin should be taken with theophylline 1 hour apart to decrease the likelihood of gastrointestinal side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.3"></a><p></p>
<h4>Sotalol</h4>
<p class="First">Telithromycin has been shown to decrease the C<span class="Sub">max</span> and AUC of sotalol by 34% and 20%, respectively, due to decreased absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.4"></a><p></p>
<h4>Warfarin</h4>
<p class="First">When co-administered with telithromycin in healthy subjects, there were no pharmacodynamic or pharmacokinetic effects on racemic warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.5"></a><p></p>
<h4>Oral contraceptives</h4>
<p class="First">When oral contraceptives containing ethinyl estradiol and levonorgestrel were co-administered with telithromycin, the steady-state AUC of ethinyl estradiol did not change and the steady-state AUC of levonorgestrel was increased by 50%. The pharmacokinetic/pharmacodynamic study showed that telithromycin did not interfere with the antiovulatory effect of oral contraceptives containing ethinyl estradiol and levonorgestrel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.6"></a><p></p>
<h4>Ranitidine, antacid</h4>
<p class="First">There was no clinically relevant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> of ranitidine or antacids containing aluminum and magnesium hydroxide on telithromycin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.6.7"></a><p></p>
<h4>Rifampin</h4>
<p class="First">During concomitant administration of rifampin and KETEK in repeated doses, C<span class="Sub">max</span> and AUC of telithromycin were decreased by 79%, and 86%, respectively. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS, Drug Interactions</a></span>)</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Telithromycin belongs to the ketolide class of antibacterials and is structurally related to the macrolide family of antibiotics. Telithromycin concentrates in phagocytes where it exhibits activity against intracellular respiratory pathogens. <span class="Italics">In vitro</span>, telithromycin has been shown to demonstrate concentration-dependent bactericidal activity against isolates of <span class="Italics">Streptococcus pneumoniae</span> (including multi-drug resistant isolates [MDRSP<a name="footnote-reference-3" href="#footnote-3" class="Sup">1</a>]).</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">1</a></dt>
<dd>MDRSP=Multi-drug resistant <span class="Italics">Streptococcus pneumoniae </span>includes isolates known as PRSP (penicillin-resistant <span class="Italics">Streptococcus pneumoniae</span>), and are isolates resistant to two or more of the following antimicrobials: penicillin, 2<span class="Sup">nd</span> generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. </dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.1"></a><p></p>
<h3>Mechanism of action</h3>
<p class="First">Telithromycin blocks protein synthesis by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci (e.g., <span class="Italics">Streptococcus pneumoniae</span>) in the presence of resistance mediated by methylases (<span class="Italics">erm </span>genes) that alter the domain V binding site of telithromycin. Telithromycin may also inhibit the assembly of nascent ribosomal units.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.2"></a><p></p>
<h3>Mechanism of resistance </h3>
<p class="First"><span class="Italics">Staphylococcus aureus</span> and<span class="Italics"> Streptococcus pyogenes</span> with the constitutive macrolide-lincosamide-streptogramin B (cMLS<span class="Sub">B</span>) phenotype are resistant to telithromycin.</p>
<p>Mutants of <span class="Italics">Streptococcus pneumoniae </span>derived in the laboratory by serial passage in subinhibitory concentrations of telithromycin have demonstrated resistance based on L22 riboprotein mutations (telithromycin MICs are elevated but still within the susceptible range), one of two reported mutations affecting the L4 riboprotein, and production of K-peptide. The clinical significance of these laboratory mutants is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.3"></a><p></p>
<h3>Cross resistance</h3>
<p class="First">Telithromycin does not induce resistance through methylase gene expression in erythromycin-inducibly resistant bacteria, a function of its 3-keto moiety. Telithromycin has not been shown to induce resistance to itself.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.4"></a><p></p>
<h3>List of Microorganisms</h3>
<p class="First">Telithromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical settings as described in the <span class="Bold"><a href="#Indications">INDICATIONS AND USAGE</a></span> section.</p>
<p><span class="Italics">Aerobic gram-positive microorganisms</span></p>
<p><span class="Italics">Streptococcus pneumoniae </span>(including multi-drug resistant isolates [MDRSP<a name="footnote-reference-4" href="#footnote-4" class="Sup">2</a>])</p>
<p><span class="Italics">Aerobic gram-negative microorganisms</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Moraxella catarrhalis</span></p>
<p><span class="Italics">Other microorganisms</span></p>
<p><span class="Italics">Chlamydophila (Chlamydia) pneumoniae</span></p>
<p><span class="Italics">Mycoplasma pneumoniae</span></p>
<p>The following <span class="Italics">in vitro </span>data are available, but their clinical significance is unknown. </p>
<p>At least 90% of the following microorganisms exhibit <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) less than or equal to the susceptible breakpoint for telithromycin. However, the safety and efficacy of telithromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><span class="Italics">Aerobic gram-positive microorganisms</span></p>
<p><span class="Italics">Staphylococcus aureus</span> (methicillin and erythromycin susceptible isolates only)</p>
<p><span class="Italics">Streptococcus pyogenes</span> (erythromycin susceptible isolates only)</p>
<p>Streptococci (Lancefield groups C and G)</p>
<p><span class="Italics">Other microorganisms</span></p>
<p><span class="Italics">Legionella pneumophila</span></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">2</a></dt>
<dd>MDRSP=Multi-drug resistant <span class="Italics">Streptococcus pneumoniae </span>includes isolates known as PRSP (penicillin-resistant <span class="Italics">S. pneumoniae</span>), and are isolates resistant to two or more of the following antimicrobials: penicillin, 2<span class="Sup">nd</span> generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.5"></a><p></p>
<h3>Susceptibility Test Methods</h3>
<p class="First">When available, the clinical microbiology laboratory should provide cumulative results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antimicrobial. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.5.1"></a><p></p>
<h4>Dilution techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antibacterial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution methods (broth or agar dilution)<span class="Sup">1,3</span> or equivalent with standardized inoculum and  concentrations of telithromycin powder. The MIC values should be interpreted according to criteria provided in Table 3.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.5.2"></a><p></p>
<h4>Diffusion techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antibiotics. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 µg telithromycin to test the susceptibility of microorganisms to telithromycin. Disc diffusion zone sizes should be interpreted according to criteria in Table 3.</p>
<a name="idc82f953-404f-4899-8db5-67f5a58a033e"></a><table width="75%">
<caption><span>Table 3. Susceptibility Test Result Interpretive Criteria for Telithromycin</span></caption>
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="14%">
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="14%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3">Minimal Inhibitory Concentrations<br>(µg/mL)</th>
<th align="center" colspan="3">Disk Diffusion<br>(zone diameters in mm)</th>
</tr>
<tr class="Last">
<th align="left">Pathogen</th>
<th align="left">S</th>
<th align="left">I</th>
<th align="left">R</th>
<th align="left">S</th>
<th align="left">I</th>
<th align="left">R </th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Streptococcus</span><br><span class="Italics">pneumoniae</span>
</td>
<td align="left" valign="bottom">≤ 1</td>
<td align="left" valign="bottom">2</td>
<td align="left" valign="bottom">≥ 4</td>
<td align="left" valign="bottom">≥ 19</td>
<td align="left" valign="bottom">16–18</td>
<td align="left" valign="bottom">≤ 15</td>
</tr>
<tr class="Last">
<td align="left" valign="bottom">
<span class="Italics">Haemophilus</span><br><span class="Italics">influenzae</span>
</td>
<td align="left" valign="bottom">≤ 4</td>
<td align="left" valign="bottom">8</td>
<td align="left" valign="bottom">≥ 16</td>
<td align="left" valign="bottom">≥ 15</td>
<td align="left" valign="bottom">12–14</td>
<td align="left" valign="bottom">≤ 11</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antibacterial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.5.3"></a><p></p>
<h4>Quality control</h4>
<p class="First">Standardized susceptibility test procedures require the use of quality control microorganisms to determine the performance of the test procedures<span class="Sup">1,2,3</span>. Standard telithromycin powder should provide the MIC ranges for the quality control organisms in Table 4. For the disk diffusion technique, the 15-µg telithromycin disk should provide the zone diameter ranges for the quality control organisms in Table 4. </p>
<a name="ia23c27be-0b1e-45e8-82e2-ad68f90256dd"></a><table width="75%">
<caption><span>Table 4. Acceptable Quality Control Ranges for Telithromycin</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th align="left" valign="top">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span><br>(µg/mL)</th>
<th align="center" valign="top">Disk Diffusion<br>(Zone diameter in mm)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">ATCC = American Type Culture Collection</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Italics">Streptococcus pneumoniae</span><br>ATCC 49619</td>
<td align="left" valign="bottom">               0.004–0.03</td>
<td align="center" valign="bottom">27–33</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Haemophilus influenzae</span><br>ATCC 49247</td>
<td align="left" valign="bottom">               1.0–4.0</td>
<td align="center" valign="bottom">17–23</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Indications"></a><a name="section-3.5"></a><p></p>
<h2>INDICATIONS AND USAGE</h2>
<p class="First">KETEK tablets are indicated for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (of mild to moderate severity) due to<span class="Italics"> Streptococcus pneumoniae</span>, (including multi-drug resistant isolates [MDRSP<a name="footnote-reference-5" href="#footnote-5" class="Sup">3</a>]), <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, <span class="Italics">Chlamydophila pneumoniae</span>, or <span class="Italics">Mycoplasma pneumoniae</span>, for patients 18 years old and above.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">3</a></dt>
<dd>MDRSP, Multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span> includes isolates known as PRSP (penicillin-resistant <span class="Italics">Streptococcus pneumoniae</span>), and are isolates resistant to two or more of the following antibiotics: penicillin, 2<span class="Sup">nd</span> generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">KETEK is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</span> Exacerbations of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> have been reported in patients and sometimes occurred within a few hours of the first dose of telithromycin. Reports have included fatal and life-threatening <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> with a rapid onset and progression.</p>
<p>KETEK is contraindicated in patients with previous history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and/or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> associated with the use of KETEK tablets, or any macrolide antibiotic.</p>
<p>KETEK is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to telithromycin and/or any components of KETEK tablets, or any macrolide antibiotic.</p>
<p>Concomitant administration of KETEK with cisapride or pimozide is contraindicated. (See <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL PHARMACOLOGY, Drug-drug Interactions</a></span> and <span class="Bold"><a href="#Precautions">PRECAUTIONS</a></span>.)</p>
<p>Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (See <span class="Bold"><a href="#W_DI">WARNINGS, Drug Interactions</a></span> and <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS, Drug interactions</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">Acute hepatic failure</span> and severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, in some cases fatal, have been reported in patients treated with KETEK.  These hepatic reactions included fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> leading to liver transplant, and were observed during or immediately after treatment</span>. In some of these cases, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> progressed rapidly and occurred after administration of a few doses of KETEK<span class="Bold">.</span> (See <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a></span>) </p>
<p>Physicians and patients should monitor for the appearance of signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4172937" conceptname="Bilirubinuria">bilirubinuria</span>, acholic stools, <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span> or <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>.  <span class="Bold">Patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> must be advised to discontinue KETEK and immediately seek medical evaluation, which should include liver function tests</span>. (See <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a>, <a href="#Information">PRECAUTIONS, Information to Patients</a></span>.)  If clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or transaminase elevations combined with other systemic symptoms occur, KETEK should be permanently discontinued.</p>
<p>Ketek must not be re-administered to patients with a previous history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and/or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> associated with the use of KETEK tablets, or any macrolide antibiotic.  (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>)</p>
<p>In addition, less severe hepatic dysfunction associated with increased liver enzymes, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and in some cases <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> was reported with the use of KETEK. These events associated with less severe forms of liver toxicity were reversible. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>QTc prolongation</h2>
<p class="First">Telithromycin has the potential to prolong the QTc interval of the electrocardiogram in some patients. QTc prolongation may lead to an increased risk for <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. Thus, telithromycin should be avoided in patients with congenital prolongation of the QTc interval, and in patients with ongoing proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and in patients receiving Class IA (e.g., quinidine and procainamide) or Class III (e.g., dofetilide) antiarrhythmic agents.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> have been reported post-marketing with KETEK. In clinical trials, no cardiovascular morbidity or mortality attributable to QTc prolongation occurred with telithromycin treatment in 4780 patients in clinical trials, including 204 patients having a prolonged QTc at baseline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>*</h2>
<p class="First"><span class="Bold">KETEK may cause <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> particularly in slowing the ability to accommodate and the ability to release accommodation.</span> <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> included <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, difficulty focusing, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>. Most events were mild to moderate; however, severe cases have been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">Loss of Consciousness</span>*</h2>
<p class="First"><span class="Bold">There have been post-marketing adverse event reports of transient <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> including some cases associated with vagal syndrome.</span></p>
<p><span class="Bold">*Because of potential visual difficulties or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, patients should attempt to minimize activities such as driving a motor vehicle, operating heavy machinery or engaging in other hazardous activities during treatment with KETEK. If patients experience visual disorders or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> while taking KETEK, patients should not drive a motor vehicle, operate heavy machinery or engage in other hazardous activities.</span><br> (See <span class="Bold"><a href="#Information">PRECAUTIONS, Information for Patients</a></span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="W_DI"></a><a name="section-5.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Serious adverse reactions have been reported in patients taking KETEK concomitantly with CYP 3A4 substrates. These include colchicine toxicity with colchicine; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with simvastatin, lovastatin, and atorvastatin; and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with calcium channel blockers metabolized by CYP 3A4 (e.g., verapamil, amlodipine, diltiazem). (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS, Drug interactions</a></span>.)</p>
<p>Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong CYP 3A4 inhibitors. Telithromycin is a strong CYP 3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of telithromycin and colchicine is necessary in patients with normal renal and hepatic function, the dose of colchicine should be reduced. Patients should be monitored for clinical symptoms of colchicine toxicity. Concomitant administration of KETEK and colchicine is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS, Drug interactions</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including KETEK, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C difficile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="General"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing KETEK in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Telithromycin is principally excreted via the liver and kidney. Telithromycin may be administered without dosage adjustment in the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min), a reduced dosage of KETEK is recommended. (See <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a></span>)</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Information"></a><a name="section-6.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">A Medication Guide is provided to patients when Ketek is dispensed. Patients should be instructed to read the MedGuide when Ketek is received. In addition, the complete text of the MedGuide is reprinted at the end of this document.</p>
<p>The following information and instructions should be communicated to the patient.</p>
<ul><li>KETEK may cause problems with vision particularly when looking quickly between objects close by and objects far away.  These events include <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, difficulty focusing, and objects looking doubled. Most events were mild to moderate; however, severe cases have been reported. Problems with vision were reported as having occurred after any dose during treatment, but most occurred following the first or second dose. These problems lasted several hours and in some patients came back with the next dose. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> and <span class="Bold"><a href="#Adverse_Reactions">ADVERSE REACTIONS</a>.</span>)</li></ul>
<p>Patients should be advised that avoiding quick changes in viewing between objects in the distance and objects nearby may help to decrease the effects of these visual difficulties.</p>
<ul><li><span class="Bold">Because of potential visual difficulties, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, patients should attempt to minimize activities such as driving a motor vehicle, operating heavy machinery or engaging in other hazardous activities during treatment with KETEK.  </span></li></ul>
<p>If patients experience visual difficulties, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> / <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span></p>
<ul>
<li>patients should seek advice from their physician before taking another dose</li>
<li>patients should not drive a motor vehicle, operate heavy machinery, or engage in otherwise hazardous activities.</li>
</ul>
<p>Patients should also be advised:</p>
<ul>
<li>
<span class="Bold">Ketek is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. </span><br>(See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>)</li>
<li>of the possibility of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, associated with KETEK, which in rare cases may be severe. <span class="Bold">Patients developing signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> should be instructed to discontinue KETEK and seek medical attention immediately.</span> Symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine, light-colored stools, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, or tender abdomen. Ketek must not be taken by patients with a previous history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>/<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> associated with the use of KETEK or macrolide antibiotics.<br>(See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#Warnings">WARNINGS</a></span>)</li>
<li>antibacterial drugs including KETEK should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When KETEK is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by KETEK or other antibacterial drugs in the future.</li>
<li>KETEK has the potential to produce changes in the electrocardiogram (QTc interval prolongation) and that they should report any <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> occurring during drug treatment.</li>
<li>KETEK should be avoided in patients receiving Class 1A (e.g., quinidine, procainamide) or Class III (e.g., dofetilide) antiarrhythmic agents.</li>
<li>to inform their physician of any personal or family history of QTc prolongation or proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, or clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible<span class="Bold">.</span>
</li>
<li>simvastatin, lovastatin, or atorvastatin should be avoided in patients receiving KETEK.  If KETEK is prescribed, therapy with simvastatin, lovastatin, or atorvastatin should be stopped during the course of treatment. (See <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL  PHARMACOLOGY, Drug-drug interactions</a></span>)</li>
<li>colchicine should be avoided in patients receiving KETEK. If KETEK is prescribed in patients with normal kidney and liver function, the dose is colchicine should be reduced.  Concomitant treatment with KETEK and colchicine is contraindicated in patients with kidney or liver impairment. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a> and <a href="#W_DI">WARNINGS, Drug interactions</a>.</span>)</li>
<li>KETEK tablets can be taken with or without food.</li>
<li>to inform their physician of any other medications taken concurrently with KETEK, including over-the-counter medications and dietary supplements.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_Interactions"></a><a name="section-6.3"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">Telithromycin is a strong inhibitor of the cytochrome P450 3A4 system. Co-administration of KETEK tablets and a drug primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentration of the drug co-administered with telithromycin that could increase or prolong both the therapeutic and adverse effects. Therefore, appropriate dosage adjustments may be necessary for the drug co-administered with telithromycin.</p>
<p>The use of KETEK is contraindicated with cisapride. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL PHARMACOLOGY, Drug-drug interactions</a></span>)</p>
<p>The use of KETEK is contraindicated with pimozide. Although there are no studies looking at the interaction between KETEK and pimozide, there is a potential risk of increased pimozide plasma levels by inhibition of CYP 3A4 pathways by KETEK as with macrolides. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span>)</p>
<p>In a pharmacokinetic study, simvastatin levels were increased due to CYP 3A4 inhibition by telithromycin. (See <span class="Bold"><a href="#Other_Drug_Interactions">CLINICAL PHARMACOLOGY, Drug-drug interactions</a></span>) Similarly, an interaction may occur with lovastatin or atorvastatin but not with statins which are not metabolized by CYP3A4. </p>
<p>High levels of HMG-CoA reductase inhibitors increase the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Use of simvastatin, lovastatin, or atorvastatin concomitantly with KETEK should be avoided. If KETEK is prescribed, therapy with simvastatin, lovastatin, or atorvastatin should be suspended during the course of treatment. Patients concomitantly treated with statins should be carefully monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p>Colchicine is a substrate for both CYP 3A4 and the efflux transporter, P-glycoprotein (P-gp), and a significant increase in colchicine plasma concentration is anticipated when co-administered with strong CYP 3A4 inhibitors such as telithromycin. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#W_DI">WARNINGS, Drug interactions</a>).</span></p>
<p>Monitoring of digoxin side effects or serum levels should be considered during concomitant administration of digoxin and KETEK. (See <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL PHARMACOLOGY, Drug-drug interactions</a>.)</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmia</span> and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> have been observed in patients receiving concomitant treatment with calcium channel blockers that are substrates of CYP 3A4 (e.g., verapamil, amlodipine, diltiazem).</p>
<p>Patients should be monitored with concomitant administration of midazolam and dosage adjustment of midazolam should be considered if necessary. Precaution should be used with other benzodiazepines, which are metabolized by CYP 3A4 and undergo a high first-pass effect (e.g., triazolam). (See <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL PHARMACOLOGY, Drug-drug interactions</a>.</span>)</p>
<p>Concomitant treatment of KETEK with rifampin, a CYP 3A4 inducer, should be avoided. Concomitant administration of other CYP 3A4 inducers such as phenytoin, carbamazepine, or phenobarbital is likely to result in subtherapeutic levels of telithromycin and loss of effect. (See <span class="Bold"><a href="#Other_Drug_Interactions">CLINICAL PHARMACOLOGY, Other drug interactions</a></span>.)</p>
<p>In patients treated with metoprolol for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the increased exposure to metoprolol, a CYP 2D6 substrate, may be of clinical importance. Therefore, co-administration of KETEK and metoprolol in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> should be considered with caution. (See <span class="Bold"><a href="#Drug_Drug_Interaction">CLINICAL PHARMACOLOGY, Drug-drug interactions</a>.</span>)</p>
<p>Spontaneous post-marketing reports suggest that administration of KETEK and oral anticoagulants concomitantly may potentiate the effects of the oral anticoagulants.  Consideration should be given to monitoring <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times/INR while patients are receiving KETEK and oral anticoagulants simultaneously.</p>
<p>No specific drug interaction studies have been performed to evaluate the following potential drug-drug interactions with KETEK. However, these drug interactions have been observed with macrolide products.</p>
<p>Drugs metabolized by the cytochrome P450 system such as carbamazepine, cyclosporine, tacrolimus, sirolimus, hexobarbital, and phenytoin: elevation of serum levels of these drugs may be observed when co-administered with telithromycin.  As a result, increases or prolongation of the therapeutic and/or adverse effects of the concomitant drug may be observed.</p>
<p>Ergot alkaloid derivatives (such as ergotamine or dihydroergotamine): acute ergot toxicity characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span> has been reported when macrolide antibiotics were co-administered. Without further data, the co-administration of KETEK and these drugs is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.4"></a><p></p>
<h2>Laboratory test interactions</h2>
<p class="First">There are no reported laboratory test interactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long-term studies in animals to determine the carcinogenic potential of KETEK have not been conducted.</p>
<p>Telithromycin showed no evidence of genotoxicity in four tests: gene mutation in bacterial cells, gene mutation in mammalian cells, chromosome aberration in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the micronucleus test in the mouse. </p>
<p>No evidence of impaired fertility in the rat was observed at doses estimated to be 0.61 times the human daily dose on a mg/m<span class="Sup">2</span> basis. At doses of 1.8–3.6 times the human daily dose, at which signs of parental toxicity were observed, moderate reductions in fertility indices were noted in male and female animals treated with telithromycin.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.6.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>Telithromycin was not teratogenic in the rat or rabbit. Reproduction studies have been performed in rats and rabbits, with effect on pre-post natal development studied in the rat.  At doses estimated to be 1.8 times (900 mg/m<span class="Sup">2</span>) and 0.49 times (240 mg/m<span class="Sup">2</span>) the daily human dose of 800 mg (492 mg/m<span class="Sup">2</span>) in the rat and rabbit, respectively, no evidence of fetal terata was found. At doses higher than the 900 mg/m<span class="Sup">2</span> and 240 mg/m<span class="Sup">2</span> in rats and rabbits, respectively, maternal toxicity may have resulted in delayed fetal maturation. No adverse effects on prenatal and postnatal development of rat pups were observed at 1.5 times (750 mg/m<span class="Sup">2</span>/d) the daily human dose.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Telithromycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.7"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">Telithromycin is excreted in breast milk of rats. Telithromycin may also be excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when KETEK is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.8"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">The safety and effectiveness of KETEK in pediatric patients has not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.9"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">In all Phase III clinical trials (n=4,780), KETEK was administered to 694 patients who were 65 years and older, including 231 patients who were 75 years and older. Efficacy and safety in elderly patients ≥ 65 years were generally similar to that observed in younger patients; however, greater sensitivity of some older individuals cannot be ruled out. No dosage adjustment is required based on age alone. (See <span class="Bold"><a href="#Geriatrics">CLINICAL PHARMACOLOGY, Special populations, Geriatric </a></span> and <span class="Bold"><a href="#Dosage_And_Administration">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In Phase III clinical trials, 4,780 patients (n=2702 in controlled trials) received daily oral doses of KETEK 800 mg once daily for 5 days or 7 to 10 days. Most adverse events were mild to moderate in severity. In the combined Phase III studies, discontinuation due to treatment-emergent adverse events occurred in 4.4% of KETEK-treated patients and 4.3% of combined comparator-treated patients. Most discontinuations in the KETEK group were due to treatment-emergent adverse events in the gastrointestinal body system, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (0.9% for KETEK vs. 0.7% for comparators), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.7% for KETEK vs. 0.5% for comparators).</p>
<p>All and possibly related treatment-emergent adverse events (TEAEs) occurring in controlled clinical studies in ≥ 2.0% of all patients are included below:</p>
<a name="ie2329bce-618d-41f0-86a4-8a3548bc1d35"></a><table width="90%">
<caption><span>Table 5</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="5">All and Possibly Related Treatment-Emergent Adverse Events Reported in Controlled Phase III Clinical Studies (Percent Incidence)</th></tr>
<tr>
<th class="Botrule Lrule" align="left">Adverse Event
                           </th>
<th class="Botrule Lrule" align="center" colspan="2">All TEAEs</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">Possibly-Related TEAEs</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center">KETEK<br>n= 2702 </th>
<th class="Botrule Lrule" align="center">Comparator<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a><br>n= 2139 </th>
<th class="Botrule Lrule" align="center">KETEK<br>n= 2702</th>
<th class="Botrule Lrule Rrule" align="center">Comparator<a href="#footnote-6" class="Sup">*</a><br>n= 2139</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Includes comparators from all controlled Phase III studies.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule" align="center">10.8%</td>
<td class="Botrule Lrule" align="center">8.6%</td>
<td class="Botrule Lrule" align="center">10.0%</td>
<td class="Botrule Lrule Rrule" align="center">8.0%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule" align="center">7.9%</td>
<td class="Botrule Lrule" align="center">4.6%</td>
<td class="Botrule Lrule" align="center">7.0%</td>
<td class="Botrule Lrule Rrule" align="center">4.1%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule" align="center">5.5%</td>
<td class="Botrule Lrule" align="center">5.8%</td>
<td class="Botrule Lrule" align="center">2.0%</td>
<td class="Botrule Lrule Rrule" align="center">2.5%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (excl. <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)</td>
<td class="Botrule Lrule" align="center">3.7%</td>
<td class="Botrule Lrule" align="center">2.7%</td>
<td class="Botrule Lrule" align="center">2.8%</td>
<td class="Botrule Lrule Rrule" align="center">1.5%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule" align="center">2.9%</td>
<td class="Botrule Lrule" align="center">2.2%</td>
<td class="Botrule Lrule" align="center">2.4%</td>
<td class="Botrule Lrule Rrule" align="center">1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose Stools</span></td>
<td class="Botrule Lrule" align="center">2.3%</td>
<td class="Botrule Lrule" align="center">1.5%</td>
<td class="Botrule Lrule" align="center">2.1%</td>
<td class="Botrule Lrule Rrule" align="center">1.4%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Botrule Lrule" align="center">1.6%</td>
<td class="Botrule Lrule" align="center">3.6%</td>
<td class="Botrule Lrule" align="center">1.5%</td>
<td class="Botrule Lrule Rrule" align="center">3.6%</td>
</tr>
</tbody>
</table>
<p>The following events judged by investigators to be at least possibly drug related were observed infrequently (≥ 0.2% and &lt; 2%), in KETEK-treated patients in the controlled Phase III studies.</p>
<p><span class="Bold">Gastrointestinal system: </span><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, watery stools.</p>
<p><span class="Bold">Liver and biliary system: </span><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>: increased transaminases, increased liver enzymes (e.g., ALT, AST) were usually asymptomatic and reversible. ALT elevations above 3 times the upper limit of normal were observed in 1.6%, and 1.7% of patients treated with KETEK and comparators, respectively. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurred in 0.07% of patients treated with KETEK, and was reversible. (See <span class="Bold"><a href="#General">PRECAUTIONS, General</a></span>.)</p>
<p><span class="Bold">Nervous system: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p>
<p><span class="Bold">Body as a whole: </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></p>
<p><span class="Bold">Special senses: </span>Visual adverse events most often included <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or difficulty focusing. Most events were mild to moderate; however, severe cases have been reported. Some patients discontinued therapy due to these adverse events.  Visual adverse events were reported as having occurred after any dose during treatment, but most visual adverse events (65%) occurred following the first or second dose. Visual events lasted several hours and recurred upon subsequent dosing in some patients. For patients who continued treatment, some resolved on therapy while others continued to have symptoms until they completed the full course of treatment. (See <span class="Bold"><a href="#Warnings">WARNINGS </a></span> and <span class="Bold"><a href="#Information">PRECAUTIONS, Information for patients</a></span>.)</p>
<p>Females and patients under 40 years old experienced a higher incidence of telithromycin-associated visual adverse events. (See <span class="Bold"><a href="#Clinical_Studies">CLINICAL STUDIES</a></span>.)</p>
<p><span class="Bold">Urogenital system: </span><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, vaginosis fungal</p>
<p><span class="Bold">Skin:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Hematologic:</span> increased platelet count</p>
<p><span class="Bold">Other possibly related clinically-relevant events occurring in &lt;0.2% of patients treated with KETEK from the controlled Phase III studies included: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, elevated blood bilirubin, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, increased blood alkaline phosphatase, increased eosinophil count, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Post-Marketing Adverse Event Reports</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been reported from worldwide post-marketing experience with KETEK. </p>
<p>Allergic: face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, rare reports of severe allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> </p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p>Gastrointestinal system: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p>Liver and biliary system: Hepatic dysfunction has been reported.</p>
<p>Severe and in some cases fatal hepatotoxicity, including fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported in patients treated with KETEK.  These hepatic reactions were observed during or immediately after treatment.  In some of these cases, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> progressed rapidly and occurred after administration of only a few doses of KETEK. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.) Severe reactions, in some but not all cases, have been associated with serious underlying diseases or concomitant medications.</p>
<p>Data from post-marketing reports and clinical trials show that most cases of hepatic dysfunction were mild to moderate. (See <span class="Bold"><a href="#General">PRECAUTIONS, General</a></span>.)</p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, rare reports of exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. (See <span class="Bold"><a href="#Contraindications">CONTRAINDICATIONS</a>.</span>) <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p>Nervous system: <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, in some cases associated with vagal syndrome.</p>
<p>Psychiatric disorders: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (mostly visual)</p>
<p>Special senses: taste/<span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">smell perversion</span> and/or loss</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of acute overdosage, the stomach should be emptied by gastric lavage. The patient should be carefully monitored (e.g., ECG, electrolytes) and given symptomatic and supportive treatment. Adequate hydration should be maintained. The effectiveness of hemodialysis in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation with KETEK is unknown.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage_And_Administration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of KETEK tablets is 800 mg (2 tablets of 400 mg) taken orally once every 24 hours, for 7–10 days. KETEK tablets can be administered with or without food.</p>
<p>KETEK may be administered without dosage adjustment in the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>In the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min), including patients who need dialysis, the dose should be reduced to KETEK 600 mg once daily. In patients undergoing hemodialysis, KETEK should be given after the dialysis session on dialysis days. (See <span class="Bold"><a href="#Renal_Insufficiency">CLINICAL PHARMACOLOGY, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span></a></span>.)</p>
<p>In the presence of severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> &lt; 30 mL/min), with coexisting <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the dose should be reduced to KETEK 400 mg once daily. (See <span class="Bold"><a href="#Multiple_Insufficiency">CLINICAL PHARMACOLOGY, Multiple insufficiency</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">KETEK<span class="Sup">®</span> 400 mg tablets are supplied as light-orange, oval, film-coated tablets, imprinted "H3647" on one side and "400" on the other side. These are packaged in bottles or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards (Ketek Pak™ and unit dose) as follows:</p>
<p><br>Ketek Pak™, 10-tablet cards (2 tablets per <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cavity)     (NDC 54868-5171-0)<br><br></p>
<br><div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Clinical_Studies"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (CAP)</h2>
<p class="First">KETEK was studied in four randomized, double-blind, controlled studies and four open-label studies for the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. Patients with mild to moderate CAP who were considered appropriate for oral outpatient treatment were enrolled in these trials.  Patients with severe <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> were excluded based on any one of the following: ICU admission, need for parenteral antibiotics, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> &gt; 30/minute, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, altered mental status, &lt; 90% oxygen saturation by pulse oximetry, or white blood cell count &lt; 4000/mm<span class="Sup">3</span>. Total number of clinically evaluable patients in the telithromycin group included 2016 patients.</p>
<a name="iac382db6-c6c1-4b94-8d1d-ee32b6d8a1ca"></a><table width="75%">
<caption><span>Table 6. CAP: Clinical cure rate at post-therapy follow-up (17–24 days)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Patients (n)</th>
<th class="Rrule" align="center" colspan="2">Clinical cure rate</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Controlled Studies</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>This study was stopped prematurely after trovafloxacin was restricted for use in hospitalized patients with severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">KETEK vs. clarithromycin 500 mg BID for 10 days</td>
<td class="Rrule" align="center">162</td>
<td class="Rrule" align="center">156</td>
<td class="Rrule" align="center">88.3%</td>
<td class="Rrule" align="center">88.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">KETEK vs. trovafloxacin<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> 200 mg QD for 7 to 10 days</td>
<td class="Rrule" align="center">80</td>
<td class="Rrule" align="center">86</td>
<td class="Rrule" align="center">90.0%</td>
<td class="Rrule" align="center">94.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">KETEK vs. amoxicillin 1000 mg TID for 10 days</td>
<td class="Rrule" align="center">149</td>
<td class="Rrule" align="center">152</td>
<td class="Rrule" align="center">94.6%</td>
<td class="Rrule" align="center">90.1%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">KETEK for 7 days vs. clarithromycin 500 mg BID for 10 days</td>
<td class="Rrule" align="center">161</td>
<td class="Rrule" align="center">146</td>
<td class="Rrule" align="center">88.8%</td>
<td class="Rrule" align="center">91.8%</td>
</tr>
</tbody>
</table>
<p>Clinical cure rates by pathogen from the four CAP controlled clinical trials in microbiologically evaluable patients given KETEK for 7–10 days or a comparator are displayed in Table 7.</p>
<a name="i633824d2-1b39-402e-83da-8b76ba7fb81a"></a><table width="75%">
<caption><span>Table 7. CAP: Clinical cure rate by pathogen at post-therapy follow-up (17–24 days)</span></caption>
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center">Pathogen</th>
<th class="Rrule" align="center">KETEK</th>
<th class="Rrule" align="center">Comparator</th>
</tr>
<tr class="Last"><th class="Botrule" align="center" colspan="3"></th></tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">73/78 (93.6%)</td>
<td class="Rrule" align="center">63/70 (90.0%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">39/47 (83.0%)</td>
<td class="Rrule" align="center">42/44 (95.5%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Italics">Moraxella catarrhalis</span></td>
<td class="Rrule" align="center">12/14 (85.7%)</td>
<td class="Rrule" align="center">7/9 (77.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Italics">Chlamydophila (Chlamydia) pneumoniae</span></td>
<td class="Rrule" align="center">23/25 (92.0%)</td>
<td class="Rrule" align="center">18/19 (94.7%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Italics">Mycoplasma pneumoniae</span></td>
<td class="Rrule" align="center">22/23 (95.7%)</td>
<td class="Rrule" align="center">20/22 (90.9%)</td>
</tr>
</tbody>
</table>
<p>Clinical cure rates for patients with CAP due to <span class="Italics">Streptococcus pneumoniae</span> were determined from patients in controlled and uncontrolled trials.  Of 333 evaluable patients with CAP due to <span class="Italics">Streptococcus pneumoniae</span>, 312 (93.7%) achieved clinical success.  Only patients considered appropriate for oral outpatient therapy were included in these trials.  More severely ill patients were not enrolled.  Blood cultures were obtained in all patients participating in the clinical trials of mild to moderate community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>. In a limited number of outpatients with incidental pneumococcal <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span> treated with KETEK, a clinical cure rate of 88% (67/76) has been observed. KETEK is not indicated for the treatment of severe community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> or suspected pneumococcal <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</p>
<p>Clinical cure rates for patients with CAP due to multi-drug resistant <span class="Italics">Streptococcus pneumoniae</span> (MDRSP*) were determined from patients in controlled and uncontrolled trials. Of 36 evaluable patients with CAP due to MDRSP, 33 (91.7%) achieved clinical success. </p>
<p><span class="Italics">*</span>MDRSP: Multi-drug resistant <span class="Italics">Streptococcus pneumoniae </span>includes isolates known as PRSP (penicillin-resistant <span class="Italics">Streptococcus pneumoniae)</span>, and are isolates resistant to two or more of the following antibiotics: penicillin, 2<span class="Sup">nd</span> generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</p>
<a name="i88929fbd-473a-409a-832c-00c6b2d3fab8"></a><table width="75%">
<caption><span>Table 8. Clinical cure rate for 36 evaluable patients with MDRSP treated with KETEK in studies of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center">Screening Susceptibility</th>
<th class="Rrule" align="center" colspan="2">Clinical Success in Evaluable MDRSP Patients</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">n/N<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>n = the number of patients successfully treated; N = the number with resistance to the listed drug of the 36 evaluable patients with CAP due to MDRSP.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Includes isolates tested for resistance to either tetracycline or doxycycline.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Penicillin-resistant</td>
<td class="Rrule" align="center">20/23</td>
<td class="Rrule" align="center">86.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">2<span class="Sup">nd</span> generation cephalosporin-resistant</td>
<td class="Rrule" align="center">20/22</td>
<td class="Rrule" align="center">90.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Macrolide-resistant</td>
<td class="Rrule" align="center">25/28</td>
<td class="Rrule" align="center">89.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Trimethoprim/sulfamethoxazole-resistant</td>
<td class="Rrule" align="center">24/27</td>
<td class="Rrule" align="center">88.9</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tetracycline-resistant<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</td>
<td class="Rrule" align="center">11/13</td>
<td class="Rrule" align="center">84.6</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Visual Adverse Events</h2>
<p class="First">Table 9 provides the incidence of all treatment-emergent visual adverse events in controlled Phase III studies by age and gender. The group with the highest incidence was females under the age of 40, while males over the age of 40 had rates of visual adverse events similar to comparator-treated patients.</p>
<a name="ibcd0068b-36f5-4d75-8850-195c5efe9c49"></a><table width="75%">
<caption><span>Table 9. Incidence of All Treatment-Emergent Visual Adverse Events in Controlled Phase III Studies</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Gender/Age</th>
<th class="Rrule" align="center">Telithromycin</th>
<th class="Rrule" align="center">Comparators<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>Includes all comparators combined</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Bold">Female </span><br><span class="Bold">≤ 40</span>
</td>
<td class="Rrule" align="center">2.1%<br>(14/682)</td>
<td class="Rrule" align="center">0.0%<br>(0/534)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Female </span><br><span class="Bold">&gt; 40</span>
</td>
<td class="Rrule" align="center">1.0%<br>(7/703)</td>
<td class="Rrule" align="center">0.35%<br>(2/574)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Male </span><br><span class="Bold">≤ 40</span>
</td>
<td class="Rrule" align="center">1.2%<br>(7/563)</td>
<td class="Rrule" align="center">0.48%<br>(2/417)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Male </span><br><span class="Bold">&gt; 40</span>
</td>
<td class="Rrule" align="center">0.27%<br>(2/754)</td>
<td class="Rrule" align="center">0.33%<br>(2/614)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Total</span></td>
<td class="Rrule" align="center">1.1%<br>(30/2702)</td>
<td class="Rrule" align="center">0.28%<br>(6/2139)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY</h1>
<p class="First">Repeated dose toxicity studies of 1, 3, and 6 months' duration with telithromycin conducted in rat, dog and monkey showed that the liver was the principal target for toxicity with elevations of liver enzymes and histological evidence of damage. There was evidence of reversibility after cessation of treatment. Plasma exposures based on free fraction of drug at the no observed adverse effect levels ranged from 1 to 10 times the expected clinical exposure.</p>
<p>Phospholipidosis (intracellular phospholipid accumulation) affecting a number of organs and tissues (e.g., liver, kidney, lung, thymus, spleen, gall bladder, mesenteric lymph nodes, GI-tract) has been observed with the administration of telithromycin in rats at repeated doses of 900 mg/m<span class="Sup">2</span>/day (1.8× the human dose) or more for 1 month, and 300 mg/m<span class="Sup">2</span>/day (0.61× the human dose) or more for 3–6 months.  Similarly, phospholipidosis has been observed in dogs with telithromycin at repeated doses of 3000 mg/m<span class="Sup">2</span>/day (6.1× the human dose) or more for 1 month and 1000 mg/m<span class="Sup">2</span>/day (2.0× the human dose) or more for 3 months. The significance of these findings for humans is unknown.</p>
<p>Pharmacology/toxicology studies showed an effect both in prolonging QTc interval in dogs <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> action potential duration (APD) in rabbit Purkinje fibers. These effects were observed at concentrations of free drug at least 8.8 (in dogs) times those circulating in clinical use. <span class="Italics">In vitro</span> electrophysiological studies (hERG assays) suggested an inhibition of the rapid activating component of the delayed rectifier potassium current (I<span class="Sub">Kr</span>) as an underlying mechanism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Revised December 2010</p>
<p>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>© 2010 sanofi-aventis U.S. LLC</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma      74146<br></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically – Sixth Edition; Approved Standard, NCCLS Document M7-A6, Vol. 23, No. 2, NCCLS, Wayne, PA, January, 2003.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Eighth Edition; Approved Standard, NCCLS Document M2-A8, Vol. 23, No. 1, NCCLS, Wayne, PA, January, 2003.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement; Approved Standard, NCCLS Document M2-A8 and M7-A6, Vol. 23, No. 1, NCCLS, Wayne, PA, January, 2004.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-15"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><span class="Bold">KETEK<span class="Sup">®</span> (<span class="Italics">KEE tek</span>)<br>(telithromycin)<br>Tablets</span></p>
<p>Read the Medication Guide that comes with KETEK before you start taking it and each time you get a new prescription. There may be new information.  Talk to your doctor if you have any questions about KETEK.  This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. </p>
<p><span class="Bold">What is the most important information I should know about KETEK?</span></p>
<p><span class="Bold">Do not take KETEK if you have <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> (a rare disease which causes <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>).   Worsening of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> symptoms including life-threatening breathing problems have happened in people with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> after taking KETEK, in some cases leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">KETEK can cause other serious side effects, including:</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> (hepatotoxicity). </span>Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, in some cases leading to a liver transplant or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has happened in people treated with KETEK.  Severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> has happened during treatment, even after a few doses, or right after treatment with KETEK has ended<span class="Bold">.</span>
</dd>
</dl>
<p><span class="Bold">Stop taking KETEK and call your doctor right away if you have signs of liver problems.  Do not take another dose of KETEK unless your doctor tells you to.</span></p>
<p><span class="Bold">Signs of liver problems include:</span></p>
<a name="ia29e906c-8bb2-4c2a-8272-15ad50b4c8a9"></a><table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="Botrule First Last Toprule">
<td align="left"><ul>
<li>increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>yellowing of your skin or whites of your eyes</li>
</ul></td>
<td align="left"><ul>
<li>dark colored urine (tea colored)</li>
<li>light colored stools </li>
<li>right upper belly <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy skin</span></li>
</ul></td>
</tr></tbody>
</table>
<p>Do not take KETEK if you have ever had liver problems while taking KETEK or macrolide antibiotics.  Macrolide antibiotics include:</p>
<ul class="Disc">
<li>erythromycin</li>
<li>azithromycin (Zithromax<span class="Sup">®</span>, Zmax<span class="Sup">®</span>)</li>
<li>clarithromycin (Biaxin<span class="Sup">®</span>)</li>
<li>dirithromycin   (Dynabac<span class="Sup">®</span>)</li>
</ul>
<dl>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Vision problems.</span> KETEK may cause you to have <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, trouble focusing your eyes, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>.  You may especially notice vision problems if you look quickly between objects close to you and objects far away from you.</dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span>.  KETEK</span> may <span class="Bold">cause you</span> to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, especially if you also have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>.  </dd>
</dl>
<p><span class="Bold">Do not drive, operate heavy machinery, or do other dangerous activities while taking KETEK if you have:</span></p>
<ul>
<li>vision problems</li>
<li><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li>seeing things that are not there (<span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>)</li>
</ul>
<p><span class="Bold">Stop taking KETEK and call your doctor right away if you have any of these symptoms. Do not take another dose of KETEK unless your doctor tells you to.</span></p>
<p><span class="Bold">4.   <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span>, slow heart rate, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. </span>Ketek may cause you to have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, a slow heart rate, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> when you also take certain medicines called calcium channel blockers. Calcium channel blockers include:</p>
<ul class="Disc">
<li>verapamil (Calan<span class="Sup">®</span>)</li>
<li>amlodipine (Norvasc<span class="Sup">®</span>)</li>
<li>diltiazem (Cardizem<span class="Sup">®</span>)</li>
<li>or other medications containing these products.</li>
</ul>
<p>See <span class="Bold">"<a href="#Side-effects">What are the possible side effects of KETEK?</a>"</span></p>
<p><span class="Bold">What is KETEK?</span></p>
<p>KETEK is an antibiotic.  KETEK is used to treat adults 18 years of age and older with a <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span> called "<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">community acquired pneumonia</span>" that is caused by certain germs called bacteria. </p>
<ul>
<li>KETEK is not for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>KETEK does not kill viruses like the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</li>
</ul>
<p><span class="Bold">Who should not take KETEK?</span></p>
<p>Do not take KETEK if you:</p>
<ul>
<li>have <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span></li>
<li>have had liver problems while taking KETEK or macrolide antibiotics. </li>
<li>have ever had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to telithromycin in KETEK or macrolide antibiotics.</li>
<li>take cisapride (Propulsid<span class="Sup">®</span>) or pimozide (Orap<span class="Sup">®</span>).</li>
<li>take colchicine (Colcrys<span class="Sup">®</span>) and have kidney or liver problems.</li>
</ul>
<p>Talk to your doctor before taking KETEK if you have any of the conditions listed above.</p>
<p><span class="Bold">What should I tell my doctor before taking KETEK?</span></p>
<p><span class="Bold">Before taking KETEK, tell your doctor if you:</span></p>
<ul>
<li>have liver problems</li>
<li>have a heart problem called "QTc prolongation" or have a family history of QTc prolongation</li>
<li>have other heart problems</li>
<li>are pregnant or plan to become pregnant. It is not known if KETEK will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if KETEK passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take KETEK.</li>
</ul>
<p>Tell your doctor about all of the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.  KETEK and other medicines may affect or interact with each other, sometimes causing serious side effects. </p>
<p>Especially tell your doctor if you take:</p>
<ul>
<li>colchicine (Colcrys<span class="Sup">®</span>) while you take KETEK</li>
<li>certain medicines called calcium channel blockers, such as: verapamil (Calan<span class="Sup">®</span>), amlodipine (Norvasc<span class="Sup">®</span>),  diltiazem (Cardizem<span class="Sup">®</span>), or other medications containing these products while you take KETEK</li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicines; you should not take these <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> lowering medicines while taking KETEK: <ul>
<li>simvastatin (Zocor<span class="Sup">®</span>, Vytorin<span class="Sup">®</span>)</li>
<li>lovastatin (Mevacor<span class="Sup">®</span>)</li>
<li>atorvastatin (Lipitor<span class="Sup">®</span>)</li>
</ul>
</li>
</ul>
<p>Ask your doctor if you are not sure if the medicine you take is included in the list of medicines above.</p>
<p>Know the medicines you take.  Keep a list of your medicines with you to show your doctor or pharmacist.</p>
<p>Do not take other medicines with KETEK without first checking with your doctor.  Your doctor will tell you if you can take other medicines while taking KETEK.</p>
<p><span class="Bold">How should I take KETEK?</span></p>
<ul>
<li>Take KETEK exactly as your doctor tells you.</li>
<li>Skipping doses or not taking all of an antibiotic may:<ul class="Circle">
<li>make the treatment not work as well</li>
<li>increase the chance that the bacteria will develop resistance to the antibiotic</li>
</ul>
</li>
<li>If you have kidney disease, your doctor may prescribe a lower dose for you.</li>
<li>Take KETEK with or without food.</li>
<li>Swallow KETEK tablets whole.</li>
<li>If you take too much KETEK, call your doctor, or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of KETEK?</span></p>
<p>See "<a href="#Most-Important">What is the most important information I should know about KETEK?</a>"</p>
<p>KETEK may cause serious side effects, including:</p>
<ul><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> </span>(an intestine <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>).  <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen with most antibiotics, including KETEK.  Call your doctor if you get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>.  You may also have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.   <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> can happen up to 2 months after you have finished your antibiotic.</li></ul>
<p>The most common side effects of KETEK are:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>problems with taste</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of KETEK.  For more information ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p>You may also report side effects to sanofi-aventis U.S. at 1-800-633-1610.</p>
<p><span class="Bold">How should I store KETEK?</span></p>
<ul>
<li>Store KETEK tablets at room temperature, between 59°F to 86°F (15°C to 30°C).</li>
<li><span class="Bold">Keep KETEK and all medicines out of the reach of children.</span></li>
</ul>
<p><span class="Bold">General Information about KETEK</span></p>
<ul><li>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.  Do not use KETEK for a condition for which it was not prescribed.  Do not share KETEK with other people, even if they have the same symptoms that you have. It may harm them.</li></ul>
<p>This Medication Guide summarizes the most important information about KETEK.  If you would like more information, talk with your doctor.  You can ask your doctor or pharmacist for information about KETEK that was written for healthcare professionals.   This information is also available on the KETEK website at www.KETEK.com or call 1-800-446-6267. </p>
<p><span class="Bold">What are the ingredients in KETEK?</span></p>
<p><span class="Bold">Active Ingredient:  </span>telithromycin</p>
<p><span class="Bold">Inactive Ingredients:  </span>croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, red ferric oxide, talc, titanium dioxide, and yellow ferric oxide</p>
<p>Revised December 2010</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807</p>
<p>© 2010 sanofi-aventis U.S. LLC</p>
<p>BIAXIN<span class="Sup">®</span> (clarithromycin) is a registered trademark of Abbott Laboratories.<br>ZITHROMAX<span class="Sup">®</span> (azithromycin) is a registered trademark of Pfizer Inc.<br>DYNABAC<span class="Sup">®</span> (dirithromycin) is a registered trademark of Eli Lilly and Company.<br>PROPULSID<span class="Sup">®</span> (cisapride) is a registered trademark of Johnson &amp; Johnson.<br>ORAP<span class="Sup">®</span> (pimozide) is a registered trademark of Teva Pharmaceuticals USA, Inc.<br>LIPITOR<span class="Sup">®</span> (atorvastatin) is a registered trademark of Pfizer Inc.<br>ZOCOR<span class="Sup">®</span> (simvastatin) is a registered trademark of Merck &amp; Co Inc.<br>VYTORIN<span class="Sup">®</span> (simvastatin and ezetimibe) is a registered trademark of Merck/Schering Plough Pharmaceuticals.<br>MEVACOR<span class="Sup">®</span> (lovastatin) is a registered trademark of Merck &amp; Co Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 400 mg Tablets</h1>
<p class="First">NDC 54868-5171-0</p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 400 mg Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ba1cca98-f350-4655-88e3-6ef990779fb9&amp;name=5171.jpg"></p>
<p><span class="Bold">Ketek<span class="Sup">®</span></span><br>TELITHROMYCIN<br><span class="Bold">400</span>mg</p>
<p><span class="Bold">Dispense with attached Medication Guide</span></p>
<p><span class="Bold">10-</span>Tablets Ketek Pak<span class="Sup">™</span><br></p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETEK 		
					</strong><br><span class="contentTableReg">telithromycin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5171(NDC:0088-2225)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>telithromycin</strong> (telithromycin) </td>
<td class="formItem">telithromycin</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H3647;400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5171-0</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021144</td>
<td class="formItem">10/27/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ce3e7997-b925-4b07-994e-b2e699e0d3a1</div>
<div>Set id: ba1cca98-f350-4655-88e3-6ef990779fb9</div>
<div>Version: 1</div>
<div>Effective Time: 20120502</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
